

ANDREW M. CUOMO Governor HOWARD A. ZUCKER, M.D., J.D. Commissioner SALLY DRESLIN, M.S., R.N. Executive Deputy Commissioner

Medicaid Fee- for- Service Providers Dispense Brand Name Drug when Less Expensive than Generic Program

Effective December 6, 2018, the following changes will be made to the Dispense Brand Name Drug when Less Expensive than Generic Program:

- Diastat, Vigamox and Xenazine will be REMOVED from the program
- Adcirca, Albenza and will be ADDED to the program

In conformance with State Education Law which intends that patients receive the lower cost alternative, brand name drugs included in this program:

- Do not require 'Dispense as Written' (DAW) or 'Brand Medically Necessary' on the prescription.
- Have a generic copayment.
- Are paid at the Brand Name Drug reimbursement rate or usual and customary price, whichever is lower (SMAC/FUL are not applied).
- Do not require a new prescription if the drug is removed from this program.

IMPORTANT BILLING INFORMATION

Prescription claims submitted to the Medicaid program **do not require** the submission of Dispense as Written/Product Selection Code of '1'; **Pharmacies can submit any valid NCPDP field (408-D8) value.**

Adcirca	Focalin	Retin-A cream
Adderall XR	Focalin XR	Suboxone 8mg/2mg film
Aggrenox	Fosrenol chew tablet	Suprax suspension
Albenza	Gleevec	Sustiva tablet
Alphagan P 0.15%	Hepsera	Tegretol suspension
Androgel pump & packets	Kapvay	Tobradex suspension
Butrans	Kitabis	Transderm-Scop
Catapres-TTS	Lexiva tablet	Trizivir
Cellcept suspension	Methylin solution	Voltaren Gel
Cipro oral suspension	Norvir tablet	Xeloda
Copaxone 20mg	Protopic	Zyflo CR
Exelon Patch	Pulmicort respule 1mg	

List of Brand Name Drugs included in this program*

*List is subject to change

Please keep in mind that drugs in this program may be subject to prior authorization requirements of other pharmacy programs, promoting the use of the most cost-effective product.